T-ALL
Clinical trials for T-ALL explained in plain language.
Never miss a new study
Get alerted when new T-ALL trials appear
Sign up with your email to follow new studies for T-ALL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough leukemia: targeted drug shows promise in relapsed T-ALL trial
Disease control Recruiting nowThis study tests a drug called isatuximab in 40 adults with a rare and aggressive leukemia (T-ALL) that has returned or not responded to standard therapy. The drug targets a protein (CD38) on the leukemia cells to help the immune system attack them. The goal is to see if it can b…
Matched conditions: T-ALL
Phase: PHASE2 • Sponsor: Goethe University • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
Engineered immune cells take aim at tough childhood leukemias
Disease control Recruiting nowThis early-phase trial tests a new treatment called CD123-CAR T cells for children and young adults up to age 21 with certain blood cancers (AML, MDS, ALL, or BPDCN) that have come back or not responded to standard therapy. The treatment involves collecting the patient's own immu…
Matched conditions: T-ALL
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 06, 2026 16:03 UTC